Regeneron Pharmaceuticals
In Mason Hawkins's portfolio · Longleaf Partners
Ticker REGN
Still in the portfolio as of Q3 2026. Every quarter it shows up in a Longleaf Partners 13F, newest first.
| Quarter | Activity | Shares | Weight |
|---|---|---|---|
| Q3 2026 | Reduce 8% | 140,165 | 5.8% |
| Q2 2026 | Add 17% | 152,322 | 5.0% |
| Q1 2026 | Reduce 21% | 130,662 | 5.0% |
| Q4 2025 | Add 15% | 165,792 | 5.7% |
| Q3 2025 | Reduce 10% | 144,607 | 4.2% |
| Q2 2025 | Add 40% | 160,581 | 4.3% |
| Q1 2025 | Buy | 114,880 | 3.9% |
Price is the position's value divided by its shares, at the end of each quarter. Share counts are as filed; when a stock split happened, the change is measured on split-adjusted shares.